Isovue^® (iopamidol injection) is a safe and effective nonionic contrast medium well established with U.S. clinical experience since 1986.  Worldwide, more than 250 million doses of iopamidol have been administered.  Indicated for a wide variety of radiological procedures, Isovue offers desired flexibility by providing a wide range of iodine concentrations and packaging options. Isovue Multipack^® Pharmacy Bulk package offers multi-dosing efficiency in 200 mL and 500 mL volumes.

Isovue-370 is the highest concentration of contrast approved for CT in the U.S. and is an excellent agent to match the speed and power of MDCT.  Isovue-M^® is indicated for myleography and is another example of the Bracco commitment to support specialized imaging applications.

IMPORTANT SAFETY INFORMATION:

ISOVUE^® (iopamidol injection) is not for intrathecal use.  Iopamidol injection is available as ISOVUE-M^® for intrathecal administration.

Nonionic iodinated contrast media inhibit blood coagulation, in vitro, less than ionic contrast media.  Clotting has been reported when blood remains in contact with syringes containing nonionic contrast media.  Serious, rarely fatal, thromboembolic events causing myocardial infarction and stroke have been reported during angiographic procedures with both ionic and nonionic contrast media.  Therefore, meticulous intravascular administration tech­nique is necessary, particularly during angiographic procedures, to minimize thromboembolic events.

Caution must be exercised in patients with severely impaired renal function, those with combined renal and hepatic disease, or anuria, particularly when larger or repeat doses are administered.  Radiopaque diagnostic contrast agents are potentially hazardous in patients with multiple myeloma or other paraproteinemia, particularly in those with therapeutically resistant anuria.  Caution should be exercised in hydrating patients with underlying conditions that may be worsened by fluid overload, such as congestive heart failure.  Diabetic nephropathy may predispose to acute renal impairment following intravascular contrast media administration.  Acute renal impairment following contrast media administration may precipitate lactic acidosis in patients who are taking biguanides.  Preparatory dehydration is dangerous and may contribute to acute renal failure in patients with advanced vascular disease, diabetic patients, and in susceptible nondiabetic patients (often elderly with preexisting renal disease).  Patients should be well hydrated prior to and following iopamidol administration.  

The possibility of a reaction, including serious, life-threatening, fatal, anaphylactoid or cardiovascular reactions, should always be considered.  Patients at increased risk include those with a history of a previous reaction to a contrast medium, patients with a known sensitivity to iodine per se, and patients with a known clinical hypersensitivity (bronchial asthma, hay fever, and food allergies). 

Isovue, Isovue-M and Isovue Multipack are currently manufactured for Bracco at two locations (Nycomed GmbH [previously Altana], Singen, Germany and Patheon Italia SpA, Ferentino, Italy). Package inserts from both sites are identical in content except for the manufacturers information.

Download pdf file	Package Insert	Material Safety Data Sheet
Isovue-200
Isovue-250
Isovue-300
Isovue-370
Isovue-M200
Isovue-M300
Isovue-Multipack